Male breast carcinoma

Goss, Paul E.; Reid, Caroline; Pintilie, Melania; Lim, Ruth; Miller, Naomi

doi:10.1002/(sici)1097-0142(19990201)85:3<629::aid-cncr13>3.0.co;2-v

Cited by 298 publications

(94 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Survival: 5 year disease-free survival has been reported to vary from 35 to 65 % [8,27,28]. In the present series, the 5 year disease-free survival was 46.43 %.…”

Section: Resultsmentioning

confidence: 44%

“…In the present study, a mass was found in 80.95 % of patients. Other studies also report the incidence in the 80-90 % range [8][9][10]. Though, incidence as low as 13 % has also been reported [11].…”

Section: Resultsmentioning

confidence: 95%

“…Goss et al [8], in a retrospective study of 229 patients over a period of 40 years, reported that breast mass was the presenting feature in 85.6 % patient. In the present study, a mass was found in 80.95 % of patients.…”

Section: Resultsmentioning

confidence: 99%

“…Goss et al [8] reported the positive effect of adjuvant tamoxifen in both actuarial 5 year survival and disease-free survival. In the present series, all 26 hormone receptor positive patients received 5 years of adjuvant tamoxifen therapy.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Male Breast Cancer: A Clinicopathologic Study of 42 Patients in Eastern India

Shah

Bhattacharyya

Gupta

et al. 2012

Indian J Surg Oncol

View full text Add to dashboard Cite

Retrospective review of presentation, treatment and outcome of male breast cancer in a tertiary cancer centre in eastern India. Data of 42 male breast cancer (MBC) patients, who presented between April, 2001 and March, 2008 were collected from institute records with respect to epidemiological characteristics, clinical and pathological parameters, treatment pattern and outcome. This series includes 42 patients with mean age of 56 years (range 31-78 years). MBC represented 1.1 % of all breast cancer. History of lump in the breast with duration ranging from 1 month to 4 years was the most common clinical presentation (80.95 %). Histopathology found infiltrating ductal carcinoma in 35 (83.33 %), followed by papillary carcinoma in 3 (7.14 %), undifferentiated carcinoma in 2 (4.76 %), mucinous carcinoma in 1 (2.38 %) and myxofibrosarcoma in 1 (2.38 %) patient. Hormone receptor (HR) study was performed on 29 patients. Twenty six (89.7 %) patients were hormone receptor positive in that 8 (27.6 %) were ER positive and 18 (62.1 %) were ER and PR positive. 3 (10.3 %) were hormone receptor negative.Axillary lymph node dissection was performed on 30 patients. Of those, 60 % were found to be positive (pN+) and 40 % were negative (pN-). Of the patients with invasive carcinoma 2.86 % were pathologic stage I, 37.14 % stage II, 42.86 % stage III and 17.14 % stage IV. Of the 35 treated patients, total 30 (85.71 %) patients underwent surgery. The surgery consisted of a modified radical mastectomy (MRM) 24 (80 %), radical mastectomy according to Halsted (RM) 6 (20 %). Adjuvant therapy i.e. Chemotherapy and Radiotherapy was administered to the patient based upon their stage. The standard treatment for all HR positive patients was administration of tamoxifen. Based upon the follow-up information (ranging from 17 month to 136 months), 4 (14.28 %) patients developed local recurrence over 4 to 26 months (mean17.5 months) and 5 patients developed distant metastasis over 24 to132 months (mean 78 months). Disease specific survival varied from 4 months to 132 months, with a mean of 56.75 months. Thirteen out of 28 evaluable patients (46.43 %) were disease free at 5 years. Male Breast cancer is a rare disease often ignored in the community, because of which it is seeks medical attention at advanced stage. Majority of MBC are found to be HR positive, hence hormonal therapy should to be strongly considered and multicentric prospective studies are needed to improve outcome.

show abstract

“…Survival: 5 year disease-free survival has been reported to vary from 35 to 65 % [8,27,28]. In the present series, the 5 year disease-free survival was 46.43 %.…”

Section: Resultsmentioning

confidence: 44%

Section: Resultsmentioning

confidence: 95%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Male Breast Cancer: A Clinicopathologic Study of 42 Patients in Eastern India

Shah

Bhattacharyya

Gupta

et al. 2012

Indian J Surg Oncol

View full text Add to dashboard Cite

show abstract

“…Thus, swainsonine has been found to reduce tumor cell metastasis, enhance cellular immune responses and resuce solid tumor growth in mice [96]. At least part of the reason for these varied effects is because swainsonine prevents the formation of the complex chain on the 6-branch of the N-linked oligosaccharides.…”

Section: Mannosidase Inhibitorsmentioning

confidence: 99%

Glycoprotein Processing Inhibitors

Ossor¹,

Elbein²,

Ernst

et al. 2000

Carbohydrates in Chemistry and Biology

View full text Add to dashboard Cite

Men With Breast Cancer Have Better Disease-Specific Survival Than Women

El‐Tamer

Komenaka²,

Troxel³

et al. 2004

Arch Surg

View full text Add to dashboard Cite

Hypothesis:Male breast cancer patients have better disease-specific survival than carefully matched female breast cancer patients.Design: Retrospective study.Setting: University hospital. Patients and Methods:Each man in the breast cancer database at Columbia-Presbyterian Medical Center (New York, NY) between the years 1980 and 1998 was matched with a woman. Matching was done based on age and date of diagnosis, stage, and primary histologic findings. Main Outcome Measures:The overall survivals and disease-specific survivals of the male breast cancer group and female breast cancer group were compared.Results: Fifty-three male patients were matched with an equal number of female breast cancer patients. The Kaplan-Meier curves demonstrated that there was no significant difference in overall survival. The 5-and 10-year survivals for women were 0.77 and 0.51, and for men 0.77 and 0.56. When the Kaplan-Meier curves for breast cancerspecific survival were compared, however, there was a significant difference in the 5-and 10-year survivals (P =.05, log-rank test). For women, the 5-and 10-year disease-specific survival was 0.81 and 0.7, respectively, while for men it was 0.9 and 0.9, respectively. In a Cox regression analysis for time to death from breast cancer, stage was the only predictor of death that approached significance (P=.06). Conclusions:While the overall survivals were equivalent, male breast cancer patients had significantly better disease-specific survivals compared with their female counterparts. Male patients were 4 times more likely to die of other causes than their breast cancer.

show abstract

Male breast carcinoma

Cited by 298 publications

References 41 publications

Male Breast Cancer: A Clinicopathologic Study of 42 Patients in Eastern India

Male Breast Cancer: A Clinicopathologic Study of 42 Patients in Eastern India

Glycoprotein Processing Inhibitors

Men With Breast Cancer Have Better Disease-Specific Survival Than Women

Contact Info

Product

Resources

About